Kalow W - Search Results

1

Intramuscular desferrioxamine in patients with Alzheimer's disease.

Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF. Crapper McLachlan DR, et al. Among authors: kalow w. Lancet. 1991 Jun 1;337(8753):1304-8. doi: 10.1016/0140-6736(91)92978-b. Lancet. 1991. PMID: 1674295 Clinical Trial.

2

High-performance liquid chromatographic analysis of desferrioxamine. Pharmacokinetic and metabolic studies.

Kruck TP, Teichert-Kuliszewska K, Fisher E, Kalow W, McLachlan DR. Kruck TP, et al. Among authors: kalow w. J Chromatogr. 1988 Dec 9;433:207-16. doi: 10.1016/s0378-4347(00)80599-x. J Chromatogr. 1988. PMID: 3235548

3

Determination of desferoxamine and a major metabolite by high-performance liquid chromatography. Application to the treatment of aluminium-related disorders.

Kruck TP, Kalow W, McLachlan DR. Kruck TP, et al. Among authors: kalow w. J Chromatogr. 1985 May 31;341(1):123-30. doi: 10.1016/s0378-4347(00)84016-5. J Chromatogr. 1985. PMID: 4019677

4

Oxazepam as a probe of hepatic metabolism in patients with Alzheimer's disease.

Fisman M, Inaba T, Kalow W, Fox H, Merskey H, Wong C. Fisman M, et al. Among authors: kalow w. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):255-61. doi: 10.1016/0278-5846(88)90042-5. Prog Neuropsychopharmacol Biol Psychiatry. 1988. PMID: 3387586

5

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Ozdemir V, et al. Among authors: kalow w. Clin Pharmacol Ther. 1997 Sep;62(3):334-47. doi: 10.1016/S0009-9236(97)90037-0. Clin Pharmacol Ther. 1997. PMID: 9333110 Clinical Trial.

6

Method to determine the enantiomers of ibuprofen from human urine by high-performance liquid chromatography.

Nicoll-Griffith DA, Inaba T, Tang BK, Kalow W. Nicoll-Griffith DA, et al. Among authors: kalow w. J Chromatogr. 1988 Jun 24;428(1):103-12. doi: 10.1016/s0378-4347(00)83894-3. J Chromatogr. 1988. PMID: 3170663

7

Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans.

Tang BK, Kalow W. Tang BK, et al. Among authors: kalow w. Methods Enzymol. 1996;272:124-31. doi: 10.1016/s0076-6879(96)72015-3. Methods Enzymol. 1996. PMID: 8791769 No abstract available.

8

An alternative test for acetylator phenotyping with caffeine.

Tang BK, Kadar D, Kalow W. Tang BK, et al. Among authors: kalow w. Clin Pharmacol Ther. 1987 Nov;42(5):509-13. doi: 10.1038/clpt.1987.189. Clin Pharmacol Ther. 1987. PMID: 3677540

9

Haloperidol reduction can be assayed in human red blood cells.

Inaba T, Kalow W, Someya T, Takahashi S, Cheung SW, Tang SW. Inaba T, et al. Among authors: kalow w. Can J Physiol Pharmacol. 1989 Nov;67(11):1468-9. doi: 10.1139/y89-237. Can J Physiol Pharmacol. 1989. PMID: 2697459

10

Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking.

Kalow W, Tang BK. Kalow W, et al. Clin Pharmacol Ther. 1991 Jan;49(1):44-8. doi: 10.1038/clpt.1991.8. Clin Pharmacol Ther. 1991. PMID: 1988240

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters